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ABSTRACT
Introduction Pancreatic exocrine insufficiency is a 
finding in many conditions, predominantly affecting those 
with chronic pancreatitis, pancreatic cancer and acute 
necrotising pancreatitis. Patients with pancreatic exocrine 
insufficiency can experience gastrointestinal symptoms, 
maldigestion, malnutrition and adverse effects on quality 
of life and even survival.
There is a need for readily accessible, pragmatic advice 
for healthcare professionals on the management of 
pancreatic exocrine insufficiency.
Methods and analysis A review of the literature was 
conducted by a multidisciplinary panel of experts in 
pancreatology, and recommendations for clinical practice 
were produced and the strength of the evidence graded. 
Consensus voting by 48 pancreatic specialists from 
across the UK took place at the 2019 Annual Meeting of 
the Pancreatic Society of Great Britain and Ireland annual 
scientific meeting.
Results Recommendations for clinical practice in the 
diagnosis, initial management, patient education and long 
term follow up were developed. All recommendations 
achieved over 85% consensus and are included within 
these comprehensive guidelines.
INTRODUCTION
Failure of the exocrine pancreas, referred to 
as pancreatic exocrine insufficiency (PEI), 
results in malnutrition, due to malabsorp-
tion of nutrients,1 2 the catabolic effects of 
the underlying pancreatic pathology and the 
impact of the disease on oral intake.3
Clinically, patients with PEI can present with 
non- specific gastrointestinal (GI) symptoms 
reflecting maldigestion, including steator-
rhoea, weight loss, diarrhoea, abdominal 
pain and bloating.4 Consequently, patients 
may experience symptoms for prolonged 
periods before PEI is diagnosed.5
It is increasingly recognised that PEI 
adversely affects survival.6 7 Pancreatic 
enzyme replacement therapy (PERT) is the 
cornerstone of treatment and is associated 
with improved survival and quality of life 
(QoL) in patients with PEI.8–10
PEI may be underdiagnosed and under-
treated in the UK, as demonstrated in other 
European countries.11 Patient support groups 
report management of PEI as the most 
common concern raised on their patient 
helpline (Pancreatic Cancer UK, 2015), 
and ‘difficulty in managing GI problems, 
diet and digestion’ are documented as the 
primary unmet need in patients with pancre-
atic cancer (PC).12 In addition, patients with 
chronic pancreatitis (CP) feel unsupported 
by healthcare professionals (HCPs) in the 
management of PEI (Pancreatitis Supporters 
Network, 2015). Consequently, there is a 
need for readily accessible, pragmatic advice 
for both specialist and non- specialist HCPs. 
The aim of this article is to provide evidence- 
based guidance on the diagnosis and manage-
ment of PEI, including differential diagnosis 
and follow- up. This article does not make 
detailed recommendations regarding the 
management of cystic fibrosis (CF) as this is 
covered in depth in other guidelines and is 
outside the clinical expertise of the authors.
METHODOLOGY
PubMed literature searches were performed 
using the following core key words for each 
search: PERT OR pancreatin OR pancre-
atic exocrine insufficiency OR exocrine 
pancreatic insufficiency OR pancreas insuffi-
ciency OR pancreatic insufficiency. For each 
section topic, additional specific search terms 
were used (online supplemental table S1). 
English- language publications describing 
randomised controlled trials (RCTs), meta- 
analyses and observational studies were 
eligible for inclusion (cut- off date 22 May 
2020; see online supplemental material). 
The review of the literature also identified 
other relevant articles, which were added if 
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they met the inclusion criteria. The Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE) system13 was used to grade the strength of the 
recommendations (1=strong, 2=weak) and the quality of 
evidence (A=high, B=moderate, C=low). A consensus on 
the statements and GRADE scores was obtained from a 
voting panel of 48 pancreatic specialists, which included 
leading gastroenterologists, pancreatic surgeons, 
specialist dietitians, nurse specialists and research clini-
cians attending the 2019 Annual Meeting of the Pancre-
atic Society of Great Britain and Ireland annual scientific 
meeting). Statement 1.2 was added as a result of discus-
sion within this meeting, and therefore was not subject to 
consensus voting.
RESULTS
Definition and diagnosis of PEI
Statement 1.1: PEI is defined as a reduction of pancreatic exocrine 
activity in the intestine at a level that prevents normal digestion 
(grade 1C; 100% agreement)
There is now agreement across pancreatic societies, glob-
ally, for this definition.14 15 The most common cause of 
PEI is CP due to loss of functioning pancreatic paren-
chyma and reduced secretion. Although PEI due to loss 
of functioning pancreatic parenchyma is also the result 
of pancreatic cancer, pancreatic resections and CF, other 
mechanisms exist. Decreased secretion can result from 
duct obstruction (eg, in periampullary tumour), or 
secondary causes, such as reduced endogenous stimula-
tion (eg, in small bowel inflammation) and postprandial 
asynchrony (eg, after gastric surgery).16
Statement 1.2: Although the coefficient of fat absorption is 
regarded as the gold-standard diagnostic test for PEI, we 
recommend that the faecal pancreatic elastase (FEL-1) test is 
a suitable first-line test for PEI (grade 1B) (note this was not 
submitted for consensus voting)
Comments
A number of tests have been used for the diagnosis of 
PEI, including the coefficient of fat absorption (CFA), 
direct pancreatic function test (PFT), indirect 13C- la-
belled mixed triglyceride breath test and secretin injec-
tion at magnetic resonance cholangiopancreatography 
(sMRCP).17 18 These tests are not used in routine clinical 
practice in the UK,19 although some, particularly the CFA 
and direct PFT, are used in controlled clinical studies.18
FEL-1 is used in clinical practice as it is less invasive and 
readily available. FEL-1 is a measurement of a pancre-
atic exocrine- specific enzyme that is not degraded in the 
bowel lumen, is concentrated during intestinal passage 
and reflects the total overall pancreatic secretion. FEL-1 
testing requires a small amount of faeces20 and is stable 
at room temperature for 3 days.21 A FEL-1 result of <200 
µg/g stool suggests moderate PEI, while <100 µg/g 
suggests severe PEI. The sensitivity of an FEL-1 level of 
<200 µg/g for PEI, when tested in patients with known 
risk factors, has been shown to be 25%–65% in mild PEI; 
33%–100% in moderate PEI and 82%–100% in severe 
PEI. The specificity of an FEL-1 level of <200 µg/g has 
been shown to be 55%–100% (although 6 out of 7 studies 
show specificity >90%).21–28
Statement 1.3: Stool samples for FEL-1 tests should undergo 
adjustment to standardised water content, when possible. A repeat 
test should be considered when a watery sample is reported by 
the laboratory, or when no definite cause of PEI is identified, to 
ensure correct diagnosis (grade 2B; 92% agreement)
False- positive results occur when water contaminates a 
specimen, such as in diarrhoea as samples can become 
diluted.29 If watery diarrhoea is reported, discussion 
with the laboratory is advised to ensure adjustment to 
a standard water content; one study showed that lyoph-
ilisation to a standardised water content of 75% was 
successful.29 If the cause of PEI is still not identified 
after further investigation and pancreatic imaging, stool 
testing should be repeated. As FEL-1 only tests for human 
elastase, the result is unaffected if the patient is taking 
PERT.21 The FEL-1 tests available in the UK were histor-
ically monoclonal,30 although more recently, polyclonal 
tests have become available and have been shown to have 
equal performance to the FEL-1 monoclonal tests.31
Statement 1.4: Positive markers of malnutrition, including clinical 
history, anthropometric measurements or serum micronutrient 
levels including magnesium, vitamin E and retinol-binding protein/
vitamin A, can be used to support a diagnosis of PEI, if unclear. 
However, none of these markers should be considered in isolation 
when diagnosing PEI (grade 2A; 97% agreement)
A patient presenting with suspected malnutrition can 
be assessed in a number of ways. Initially, this should 
be conducted clinically by percentage weight loss; 
however, there is no agreed diagnostic percentage 
for PEI,3 32 33 and fluid balance is also important to 
consider. The Malnutrition Universal Screening Tool, 
or Nutritional Risk Screening 2002 if in hospital, are 
available. Although these tools are not specifically 
designed for PEI, they do have a high inter- rater relia-
bility (κ=0.67–1.00) to identify patients that will likely 
benefit from nutritional support.34 35 A single body 
mass index (BMI) measurement is of limited diag-
nostic use on its own and can be normal in patients 
with PEI.36 37 BMI should also be interpreted with 
caution in an obese population.1 38 Evidence for 
recording specific anthropometric measurements is 
poor or absent for patients with PEI, with limited data 
in CP.1 39 Serial readings are of most use in this setting.
PEI is associated with some deficiencies in fat- soluble 
vitamins, trace elements and plasma proteins. Low levels 
of vitamin E have consistently been reported in patients 
with PEI or steatorrhoea caused by CP or CF.40–42 Studies 
have suggested retinol- binding protein (used as a marker 
of vitamin A status) may be lower in patients with alcohol- 
induced CP and steatorrhoea compared with patients 
with CP alone,41 although incidence studies in the CP 
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population have not shown a significant difference 
between those with PEI and those without.43
Vitamin A deficiency night blindness is reported in case 
studies in patients with PEI.44 However, studies have not 
found that serum vitamin A deficiency is predictive of 
PEI.41 42 45 46
One study in patients with CP showed that serum 
magnesium <2.05 mg/dL was associated with PEI in 
univariate analysis; however, it only had a positive predic-
tive value for PEI in CP of 0.58 (95% CI 0.39 to 0.75),43 
while zinc deficiency has been associated with CP but 
not PEI specifically.47 Vitamin D deficiency has been 
shown to have a high incidence in CP (53%–66%) but no 
significant difference when PEI is present.1 41 45 48 Given 
the evidence available, no finding is specific enough to 
recommend using serum micronutrients alone as a diag-
nostic marker for PEI.
Statement 1.5: Cross-sectional imaging and an EUS (without 
secretin) cannot be used as a diagnostic test for PEI but can 
support its diagnosis and identify a cause. An abdominal CT scan 
should also be performed when PEI is diagnosed, especially to 
exclude a neoplastic cause (grade 2B; 94% agreement)
Comments
CT is recommended when investigating a clinical suspi-
cion of CP, PC or other pancreatic disease that may cause 
PEI and similar symptoms.49–51 CT has been shown to 
differentiate CP from PC in 90.4% of cases and to exclude 
other aetiologies for pain or weight loss.52 Therefore, CT 
is the investigational tool of choice to exclude a pancre-
atic tumour as a cause when a diagnosis of PEI is made.53
Morphological changes of CP, including calcification 
and main pancreatic duct dilatation, can be identified on 
CT. Pancreatic calcification is a late or severe feature of 
CP,54 with PEI present in 50% of patients with substantial 
calcification.55 However, only 47% of patients with severe 
PEI and CP were shown to have significant morpholog-
ical changes, such as atrophy and ductal dilatation on CT, 
in a study of 109 patients with CP.56 57 One study showed 
that duct dilatation, diagnosed via endoscopic retrograde 
cholangiopancreatography, has a stronger association 
with PEI (OR 5.8) than calcification (no effect).52 Paren-
chymal atrophy has been observed in 54% of patients 
with CP with CT58 and on magnetic resonance cholan-
giopancreatography (MRCP) in 20% of patients with PEI 
and 5% of patients without PEI in those with pancreatic 
pain symptoms, so is neither sensitive nor specific for 
PEI.59 In patients with CP undergoing MRCP without 
secretin, no significant difference in pancreatic duct size 
was observed between patients with or without PEI.60
Endoscopic ultrasound (EUS) can be used to identify 
very early parenchymal changes in non- calcific CP with 
a sensitivity of 84% and a specificity of 80%–100%, but 
a poor negative predictive value of 45% when compared 
with histology in high- prevalence groups, suggesting that 
histological changes can be overlooked.61–63 A single- 
centre experience has shown, in two separate studies in 
patients with CP (n=115 and 128; 30.4% and 37.5% with 
PEI, respectively), that both EUS markers and tissue stiff-
ness measurements (strain ratio) show a linear increase 
in the likelihood of patients with CP having PEI.64 65 The 
probability of PEI, in the presence of calculi in the main 
pancreatic duct, was 80%, increasing to 82.8% if the main 
duct was also dilated. A further study comparing EUS 
findings with sMRCP showed reduced pancreatic func-
tion to be present in normal EUS exams and a predictive 
value of only 50% when six EUS criteria were present in 
a group with presumed pancreatic pain but an inconclu-
sive or normal CT scan.66 Therefore, although radiolog-
ical evidence of pancreatic morphological abnormalities 
is supportive of a diagnosis of PEI, further evidence, 
including maldigestion symptoms, evidence of malab-
sorption or a positive FEL-1 test, should be sought to 
confirm a diagnosis of PEI. A summary of key PEI diag-
nostic criteria is shown in box 1.
Aetiology of PEI
Statement 2.1: PEI is common in patients with CP (grade 2A; 
95% agreement). Given the high prevalence of PEI in patients 
with severe CP, FEL-1 testing is not required and treatment 
is recommended in symptomatic patients (grade 2B; 95% 
agreement)
In CP, progressive destruction of the pancreatic tissue 
results in PEI.16 Steatorrhoea is a very late symptom that 
is associated with severe PEI and substantial decompen-
sation, and is proposed to occur when >90%–95% of 
pancreatic parenchyma or function is lost.2 16 However, 
steatorrhoea was also demonstrated in patients with more 
than 10% secretory function,2 leading to concerns these 
publications might result in late diagnosis in patients 
with less severe disease.67 In the long- term, morpholog-
ical changes, and the development of steatorrhoea or 
other malabsorption features, make PEI highly likely in 
patients with CP. Alcohol aetiology, pancreatic ductal 
obstruction, calcification and duration of disease have all 
been identified as contributing factors.68 PEI is reported 
in 94% of patients within 10 years of CP onset.37 Multivar-
iate analysis has shown an association between increased 
mortality in CP and the presence of PEI (OR 2.59).6 
Given the high probability of PEI in this setting, and the 
observed benefits of PERT, testing with FEL-1 is redun-
dant and treatment with PERT is recommended.
Statement 2.2: PEI can occur following severe AP, especially 
in those with necrosis, recurrent AP or in the presence of 
pseudocysts (grade 2B; 100% agreement). Patients with acute 
necrotising pancreatitis should be routinely started on PERT once 
they are able to consume oral intake (good practice point (GPP); 
92% agreement)
The FEL-1 test has been used to monitor the presence of 
PEI following AP. PEI prevalence, following severe and 
mild attacks of AP, has been reported as 60.5% and 55.6%, 
respectively.69 While there is some recovery in exocrine func-
tion over time, a meta- analysis of 10 initial and 39 long- term 
studies in patients with AP showed that PEI occurred at an 
overall rate of 62%, was higher in patients with severe AP 
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(66%) compared with those with mild AP (46%) (p=0.001) 
and persisted in 35% of patients on long- term follow- up, 
with a pooled prevalence of 21% and 42% in patients with 
mild and severe AP.70 While PEI was more common in those 
with necrosis (p<0.0001), there was no difference in the 
prevalence of PEI in patients with ≥50% necrosis compared 
with that in patients with <50% necrosis (p=0.172).70 In a 
long- term follow- up study in patients who took part in an 
RCT comparing open necrosectomy with a step- up drainage 
technique at a median follow- up of 86 months (±11 months), 
the incidence of PEI was 29% in patients who had a step- up 
management of their necrosis compared with 56% in 
patients who underwent an open necrosectomy (p=0.03).71
Clinical judgement should be used when considering the 
likelihood of PEI in patients following severe AP, rather than 
a straightforward ‘indicated’ or ‘not indicated’ decision. A 
patient with almost total necrosis will most likely have PEI, 
whereas a patient who has recovered from solely oedema-
tous pancreatitis, with no residual structural damage to the 
gland, may have normal exocrine function (although the 
prevalence of PEI appears to be 24%, even in this patient 
group).70 Testing after recovery can be helpful to determine 
whether long- term exocrine function is impaired. Where 
the clinician is unclear as to the likelihood or severity of PEI, 
PERT should be started to prevent nutritional compromise, 
and function tests should be requested.
Statement 2.3: PEI is common in both resectable and unresectable 
PC and is progressive in nature (grade 2A; 100% agreement). 
Given the high prevalence of PEI in this patient population, routine 
FEL-1 testing is not required, and treatment is recommended 
(grade 2B; 95% agreement)
PC induces a fibrotic reaction with a consequent reduc-
tion in exocrine function. Tumours occurring in the 
pancreatic head can directly obstruct the pancreatic 
ducts and are associated with PEI.72 PEI, gastroduodenal 
asynchrony and duodenal obstruction, are common 
in patients with unresectable PC, with PEI affecting 
66%–94% of patients at presentation.73 74 Furthermore, 
PEI is progressive in patients with unresectable PC, with 
an estimated 10% reduction in exocrine function per 
month.74 The implication is clear: if a patient with PC 
is found to have normal pancreatic function at pres-
entation, it is likely that PEI will subsequently develop. 
National guidelines advocate routine use of PERT in 
patients with unresectable PC,75 and pancreatic func-
tion tests are only needed where the cause of symptoms 
is unclear. However, despite this recommendation, three 
prospective randomised studies have reported a limited 
benefit of PERT in these patients.76–78
Surgery, particularly pancreaticoduodenectomy, is asso-
ciated with PEI as it physically reduces the volume of the 
exocrine component of the pancreas and reduces the stimu-
lation of the gland.79 80
In a meta- analysis of 693 patients with PC from nine obser-
vational cohort studies, the median prevalence of PEI was 
44% before pancreaticoduodenectomy, 20% before distal 
pancreatectomy and 25%–50% in patients with locally 
advanced PC.81
The high prevalence of PEI in patients with PC (before 
and after surgery) means that little is gained from PEI 
testing. The benefits to patient survival (see Statement 3.1) 
and QoL (see Statement 3.2) with PERT, which have been 
demonstrated in these patients, means that treatment would 
usually be indicated, regardless of the FEL-1 result.75
Less common causes of PEI
Statement 2.4: Patients with diabetes mellitus may have PEI; 
however, the exact prevalence is not clear. Those with relevant 
symptoms should be offered PERT and investigated for a 
pancreatic pathology (grade 2C; 94% agreement)
There are few large studies investigating the prevalence 
of PEI in patients with diabetes mellitus (DM), but esti-
mates of 26%–57% and 12%–36% have been reported 
Box 1 Diagnosis of PEI
PEI is highly likely with high benefit from PERT: no further 
test required as significant benefit from treatments and 
the negative predictive value of FEL-1 is not strong enough 
to prevent starting treatment
 ► Head of pancreas cancer
 ► Pre- surgery and post- surgery for head of pancreas cancer with or 
without pylorus preserving operation
 ► Total pancreatectomy
 ► Steatorrhoea or malabsorption symptoms in patients with CP with 
dilated pancreatic duct or severe pancreatic calcification
 ► Severe necrotising pancreatitis
Patients that require initial investigation with FEL-1
 ► GI symptoms of maldigestion in secondary care with or without 
known associated conditions
 ► Maldigestion symptoms: steatorrhoea, weight loss, diarrhoea, ab-
dominal pain or bloating
 ► Associated conditions: patients with coeliac disease, IBS- D, HIV, 
type 1 diabetes and acute severe pancreatitis after initial phase
Following a positive FEL-1 test
 ► A positive FEL-1 requires up-to- date cross- sectional imaging to ex-
clude developing obstructive tumour or lesion as the cause
 ► If subsequent investigation cannot find a morphological pancreatic 
cause of PEI, FEL-1 should be repeated even if patient has already 
started PERT
Perform a full malnutrition assessment with clinical 
history, and serum markers specifically including 
magnesium, vitamin E and retinol- binding protein
 ► Where FEL-1 is normal in symptomatic patients with or without 
lower- risk associated condition and suspicion of maldigestion 
occurring.
 ► When FEL-1 is low to provide a baseline for ongoing surveillance of 
micronutrient status
 ► If micronutrient deficiency is demonstrated, other causes of malab-
sorption should be considered alongside PEI
 ► In cases where there is significant weight loss or clinical signs of 
micronutrient deficiency to provide a basis for treatment
CP, chronic pancreatitis; FEL-1 faecal elastase-1; GI, gastrointestinal; HIV, 
human immunodeficiency virus; IBS- D, diarrhoea- predominant irritable bowel 
syndrome; PEI, pancreatic enzyme insufficiency; PERT, pancreatic enzyme 
replacement therapy
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for patients with type 1 and type 2 DM, respectively.82 Low 
FEL-1 levels have been associated with reduced glycaemic 
control in patients with DM (p=0.031),83 and one study 
also reported a weak association with reduced BMI.84 
Another study reported a negative correlation between 
FEL-1 level and duration of DM.83 These findings further 
support the concept that PEI may be a complication of 
DM.
One study in patients with DM and low FEL-1 (defined 
as <100 µg/g) showed that PERT reduced the frequency 
of episodes of hypoglycaemia.85 This study, however, 
included few patients with symptoms that would have 
been compatible with PEI.
Despite a high prevalence of PEI in patients with DM, 
the identification of individuals who would benefit from 
PERT, and the potential long- term effects on important 
diabetes- related outcomes, requires further investiga-
tion as PEI should be considered a symptom of a disease 
rather than a disease in its own right.
New onset diabetes in the absence of typical risk factors 
should be investigated as this may be the first sign of 
pancreatic cancer or CP.86
Statement 2.5: PEI should be considered in patients with 
symptoms of maldigestion in the absence of severe pancreatic 
disease. In these cases, FEL-1 testing should be undertaken 
(grade 2B; 100% agreement)
FEL-1 has been successfully used as a case- finding tool 
for PEI in a minority of patients with coeliac disease, 
Type 1 DM, HIV, diarrhoea- predominant irritable bowel 
syndrome (IBS- D) and difficult symptoms after bari-
atric surgery (table 1). FEL-1 levels<200 µg/g stool have 
Table 1 Prevalence of PEI, potential value of PERT and recommendations for less common causes of PEI
Condition
Prevalence of abnormal 
FEL-1
Benefit of pancreatic enzyme 
supplementation Recommendation
DM83 84 158 162–164 Type 1: 26%–44%
Type 2: 12%–20%
One RCT showing reduction in 
frequency of hypoglycaemia
Statement 2.4: Patients with DM may have PEI; 
however, the exact prevalence is not clear. Those 
with relevant symptoms should be offered PERT 
and investigated for a pancreatic pathology (grade 
2C; 94% agreement)
Elderly populations87 165 
166
11.5%–20% in patients 
50–80 years of age
1.5% in patients over 90 
years of age
No treatment studies reported Statement 2.5.1: Ageing populations may have an 
increased prevalence of PEI and, therefore, should 
be considered for testing, particularly if presenting 




10%–48% No treatment studies reported Statement 2.5.2: Patients with renal disease and 
rheumatological conditions may have an increased 
prevalence of PEI but further studies are needed 
before routine testing can be recommended (GPP; 
95% agreement)
Sjögren’s syndrome169 4% in secondary Sicca 
syndrome
No treatment studies reported
Coeliac disease170–172 Around 30% with 
diarrhoea
One RCT showing benefit for 
3 months after diagnosis. One 
open- label study showing benefit 
in those with persistent diarrhoea
Statement 2.5.3: Patients with coeliac disease on 
a gluten- free diet, but still experiencing diarrhoeal 
symptoms, should be investigated for PEI and 
treated with PERT if positive results are obtained. 
This should be reviewed at least annually as 
treatment may not need to be long term (grade 1B; 
100% agreement)
IBS- D103 104 6.1%–8.6% One open- label study showing 
improved pain, stool frequency 
and consistency
Statement 2.5.4: PEI should be considered in 
patients with IBS- D. The role of PERT in this group 
is not fully understood (grade 2C; 95% agreement).
IBD173 174 19%–30% No treatment studies reported Statement 2.5.5: Patients with inflammatory bowel 
disease and continued diarrhoeal symptoms 
should be investigated for PEI (grade 2B; 100% 
agreement)
HIV175 176 23%–54% Open- label studies showing 
improvement in diarrhoea and fat 
malabsorption
Statement 2.5.6: Patients with HIV presenting with 
steatorrhoea, diarrhoea or weight loss should be 
investigated for PEI and offered PERT if positive 
results are obtained (grade 2B; 88% agreement)
Alcohol- related liver 
disease177–180
7%–20% No treatment studies reported Statement 2.5.7: There may be an increased 
prevalence of PEI in patients with alcohol- related 
liver disease but the role of PERT in this group has 
not been examined (GPP; 89% agreement)
Somatostatin 
analogues181
24% after a median of 2.9 
months of therapy
No treatment studies reported No statement
See online supplemental material for more detail.
FEL-1 faecal elastase-1; DM, diabetes mellitus; GPP, good practice point; IBD, inflammatory bowel disease; IBS- D, diarrhoea- predominant irritable 
bowel syndrome; PEI, pancreatic enzyme insufficiency; PERT, pancreatic enzyme replacement therapy; RCT, randomised controlled trial.
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been reported in 11.5%–13.1% of patients presenting 
to secondary care clinics, and a separate study demon-
strated that 79.6% of patients with low FEL-1 responded 
to PERT,87 88 indicating that they have PEI. Follow- up 
data are required to ascertain how many of these patients 
developed pancreatic pathology.
Recommendations for other, less common, causes of 
PEI, such as coeliac disease, HIV, IBS- D and alcohol- 
related liver disease, are shown in table 1, and detailed 
supporting evidence is shown in the online supplemental 
material.
The value of PERT
Statement 3.1: PERT is associated with improved survival in 
patients with CP (grade 1C) and PC (grade 2B). Additionally, PERT 
is associated with improved nutritional status in patients with CP 
(grade 1C) and PC (grade 1C) (95% agreement)
PERT has been shown to improve symptoms and digestion 
in patients with pancreatitis.89 In patients with AP, PERT 
maintained global health status.90 Among patients with 
CP, PERT has been shown to improve fat and nitrogen 
absorption, nutritional parameters and GI symptoms.91
PEI has been shown to be an independent factor 
related to mortality in patients with CP,6 and an absence 
of PERT on discharge was an independent risk factor for 
survival in those undergoing surgery for CP.92
In a small, randomised trial conducted over an 8- week 
period in 21 patients with unresectable PC, those 
receiving PERT maintained body weight (gain 1.2%; 0.7 
kg), while patients without PERT lost body weight (loss 
3.7%; 2.2 kg) (both p=0.02). CFA increased by 12% in the 
PERT group and declined by 8% in the control group, 
but this difference did not reach statistical significance 
(p=0.13).77 An RCT in Korea failed to observe any benefit 
of PERT on body weight (p=0.381), subjective global 
assessment (p=0.18) or survival (p=0.744) compared with 
placebo over an 8- week period in 67 patients with unre-
sectable PC.76 It should be noted that patients were not 
permitted to receive H2- receptor antagonists or proton- 
pump inhibitors (PPIs) and, consequently, PERT may 
not have been effective without adequate neutralisation 
of gastric acid. The dose of PERT was also quite low at 
2×25 000 units of lipase three times daily with main meals 
and one capsule with snacks. In addition, only 43% of 
patients included had severe PEI (FEL-1 level <100 µg/g 
stool), and only a third having tumours in the pancreatic 
head (35.5% in the PERT group; 33.3% in the placebo 
group). Furthermore, although the difference was not 
statistically significant, more patients in the PERT group 
had a FEL-1 level ≥200 µg/g than those in the placebo 
group (44.1% vs 21.2%; p=0.13). Hence, this trial has 
several limitations, and the results should be interpreted 
accordingly.
Further work in exploring the potential benefits of 
PERT on survival identified a link between the severity 
of PEI and reduced survival in a non- randomised study 
of 194 patients with PC. A FEL-1 level ≤20 µg/g was an 
independent predictor of survival (HR 1.59; p=0.023).7 
Treatment with PERT appeared to improve survival 
in a recent Spanish retrospective single- centre study.9 
Patients (n=160) with unresectable PC were treated by 
different teams who either prescribed high- dose PERT, 
if needed, or did not. Median survival was significantly 
longer among patients managed by the team more likely 
to prescribe PERT (189 days; 95% CI 167.0 to 211.0 days 
vs 95.0 days; 95% CI 75.4 to 114.6 days) (HR 2.12; 95% 
CI 1.49 to 3.00; p<0.001). However, the results should be 
interpreted with caution due to potential selection bias 
arising from the retrospective non- randomised study 
design. In a retrospective study of 469 patients who had 
undergone resection of periampullary cancer, PERT was 
associated with a median increase in survival on both 
multivariate (p=0.044) and propensity- matched analyses 
(p=0.009). Survival benefit was most markedly observed 
among patients treated with PERT and with pancreatic 
duct widths of ≥3 mm (HR 0.64; 95% CI 0.47 to 0.89; 
p=0.006).8
A retrospective, population- based, propensity- matched, 
observational study in the UK matched 1614 patients with 
PC who did or did not receive PERT.8 The adjusted median 
survival time was 262% longer among PERT- treated patients 
compared with matched, non- PERT- treated controls 
(survival time ratio 2.62; 95% CI 2.27 to 3.02). This survival 
benefit was present in patients who did not receive chemo-
therapy or surgery, suggesting that this benefit was indepen-
dent of other interventions.
Overall, there are conflicting data regarding PERT and 
survival, with RCTs limited by heterogeneous populations 
and other data limited by retrospective or observational trial 
design. More robust studies are required to strengthen this 
recommendation.
Importantly, a large survey of 208 patients with PC who 
were prescribed PERT in the USA identified that only 89 
patients (66% of those prescribed PERT correctly), were 
taking their enzymes as instructed. Predominantly, this 
was due to incorrect prescriptions, with 35% of patients 
not prescribed PERT with meals and snacks. Patients who 
were taking their enzymes with meals, rather than before 
or afterwards, were more likely to gain weight (p=0.022) 
and demonstrate less maldigestion (p=0.003) and less 
steatorrhoea (p=0.04) compared with those not taking 
PERT correctly.93 The high incidence of incorrect timing 
is an important consideration when analysing data from 
studies assessing the clinical response to PERT, especially 
when data are collected retrospectively.
Statement 3.2: Treatment with PERT improves QoL in patients with 
PEI (grade 1C; 100% agreement)
While PERT is useful for treating PEI, studies that address 
whether it has a positive effect on the QoL of those taking 
it have been of variable quality. Achieving equipoise, and 
assessment over an appropriate time period, can affect study 
design and interpretation, especially in the PC cohort.
Being able to justify the pill burden associated with 
PERT by confirming an associated improvement in QoL 
is both relevant and important. While initiating PERT 
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often requires specialist input, there is an ongoing need 
for patient self- management of PERT dosing. A small 
qualitative trial explored patient experiences, recruiting 
patients who were receiving PERT for at least 6 months 
following pancreaticoduodenectomy for malignancy. 
Patients reported concerns over the use of PERT at social 
events, difficulties in remembering to take treatment 
and struggles with dose adjustment. Socially debilitating 
symptoms of PEI (excessive flatulence and steatorrhoea), 
and the importance of PERT, were also acknowledged. 
The authors concluded that education and access to 
specialist support was important to patients.94
Two cohorts of patients with PEI, secondary to CP, were 
observed over a 1- year period, with assessment at 6 months 
and 1 year. Assessment of symptoms and QoL in patients 
already receiving PERT (n=206) and in patients starting 
treatment with PERT (n=88) were compared. PERT 
dosing was not controlled by the study design. Data from 
294 patients were analysed; 256 patients completed the 
validated Gastrointestinal Quality of Life index (GIQLI). 
GIQLI scores in the untreated were significantly lower 
than those on treatment at baseline (p<0.001), but this 
difference disappeared after 6 months of treatment. The 
mean total GIQLI score improved significantly over 1 
year for the study population (p<0.001), as did all five 
subscores (symptoms scale, physical function, social 
function, emotion and medical treatment). Overall, 
both cohorts exhibited significant improvements in QoL 
(both p<0.001), suggesting that improvement in QoL 
may be sustained with continued PERT.10
Another prospective study examined the effect of PERT 
versus placebo on QoL in patients with moderate- to- severe 
AP, using the Clinical Global Impression of Disease Symp-
toms (CGIDS) tool alongside version 4 of the validated 
Functional Assessment of Cancer Therapy- Pancreas QoL 
questionnaire.90 Recruitment issues led to termination 
of the study with 56 patients enrolled, but over the 26–30 
day study period, there was an improvement in the CGIDS 
scores with numerically, but not statistically significant worse 
flatulence in the placebo group (p=0.503). Of note, was a 
FEL-1 level <200 µg/g in only 20 patients. The QoL assess-
ment also favoured the PERT group, but only the ‘emotional 
well- being’ score, demonstrated a significant improvement 
in the PERT group versus placebo (p=0.04).90
More recently, work has been undertaken to develop 
a tool to identify patient- reported outcome measures in 
patients with CP (n=91). This tool correlated well with 
GIQLI scores, and patient scores correlated with disease 
severity (p<0.0001). It could be used in future research 
to provide a less invasive measure of treatment effect.95
In summary, there are data supporting the use of PERT 
to improve QoL in patients with AP, CP and resectable 
and non- resectable PC, but further high- quality studies are 
required.
Management of PEI
Statement 4.1: Patients should consent for the porcine nature of 
PERT (GPP; 97% agreement)
All currently available PERT preparations are porcine (a 
non- porcine PERT formulation was in development, but 
it failed to meet its primary endpoint in a phase III clin-
ical trial).96 Patients should be made aware of the porcine 
origin of PERT before commencing therapy. Jewish and 
Muslim faith leaders consent to the use of PERT as there 
are no alternatives available.97
Statement 4.2: PERT should be started at a dose of at least 50 000 
units lipase with meals and 25 000 units lipase with snacks (grade 
1A), and patients should be encouraged to adjust their dose if this 
is ineffective (grade 2C) (92% agreement)
The choice of PERT preparation needs to consider the 
lipase units the patient requires and the number and size 
of capsules the patient is able to swallow. Studies support 
the use of at least 50 000 units lipase as a suitable starting 
dose with meals and 25 000 units lipase with snacks.91 98 
All guidelines endorse dose escalation if the initial dose 
is not effective.77 99 100
Statement 4.3: Consumption of pancreatic enzymes should be 
spread out throughout a meal (grade 1C; 100% agreement)
A study examining the timing of PERT in 24 patients 
with CP suggested that spreading the dose throughout 
the meal supported optimal absorption.101 However, this 
trial was limited by strict exclusion criteria: no pancre-
atic or GI surgery, no antiacid therapy, no gastro paresis, 
no excessive alcohol intake or malignancy, no opiate 
prescription and the use of a prokinetic prior to the 
test.101 These data were supported by a survey of 262 
patients, which demonstrated that patients consuming 
PERT throughout meals experienced fewer abdominal 
symptoms and more weight gain compared with patients 
who consumed PERT before or after meals.93
Statement 4.4: If capsules cannot be swallowed, they should be 
opened, placed on an acidic puree and swallowed at intervals 
throughout the meal, and the mouth should be rinsed with cool 
water to prevent ulceration (GPP; 97% agreement)
Some patients are unable to swallow capsules. In those 
circumstances, the capsules can be opened and the 
contents taken on a spoonful of cold acidic food, such 
as fruit puree, apple sauce, jam or fruit yoghurt and swal-
lowed immediately.
This should then be washed down with a cool or room- 
temperature drink to ensure that no granules remain in 
the mouth, where they could cause ulceration. Special 
care should be taken by those who wear dentures. Gran-
ules should not be chewed or crushed as this removes the 
enteric coating, resulting in premature activation of the 
enzymes.
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Statement 4.5: There is no maximum dose of PERT in adults (GPP); 
however, where doses exceed 100,000 units lipase with meals, 
comorbidities should be excluded (GPP; 91% agreement)
The most frequently documented side effects of PERT 
are nausea, vomiting and abdominal discomfort. Further 
details of rarer side effects can be found in Statement 7.1.
The product itself does not raise toxicity concerns in 
the event of unnecessary or excess treatment. However, 
pill burden should be considered, and when dose escala-
tion has not resolved ongoing symptoms, comorbidities 
should be considered (see Statement 5.1).
Statement 4.6: Dietary fat restriction is not routinely 
recommended, but very high-fibre diets should be avoided (grade 
1C; 96% agreement)
Some patients require a high- fat, high- protein diet if 
they are nutritionally depleted and have a low appetite. 
Increasing the fat content of the diet has been shown to 
be well tolerated in patients with CP.102 103 Low- fat diets 
may exacerbate malnutrition and should be avoided, 
unless there is a specific reason for fat intolerance. Very 
high- fibre diets (>25 g/day) may absorb enzymes and 
delay nutrient absorption and, therefore, are not recom-
mended.104
Statement 4.7: Where needed, enteral feeds should be peptide and 
medium-chain triglyceride-based (grade 2C; 100% agreement)
One small pilot study examined the use of peptide versus 
polymeric feeds in patients with severe AP.105 Nutritional 
status and biochemical markers were assessed 2 weeks 
into the study. In populations with severe AP, it is unlikely 
that any significant change would be observed within this 
time period. While the study concluded that there was 
no difference between the two feed types, analysis of the 
secondary endpoints, including weight loss and length of 
stay, demonstrated an improvement in the peptide- fed 
group, suggesting that malabsorption of feed, secondary 
to PEI, has an impact on recovery.105 Other guidelines 
have used extrapolated data from studies comparing 
enteral and parenteral nutrition to make strong recom-
mendations regarding the use of peptide- based feeds 
(grade A), but these data support enteral over paren-
teral nutrition, rather than a specific feed,106 resulting in 
conflicting recommendations.107
Statement 4.8: Both acid (grade 1C) and temperature (GPP) 
impact the efficacy of PERT. The addition of a PPI can be useful 
if PERT is not effective (grade 1C, 97% agreement). If one PERT 
product remains ineffective, despite the use of a PPI, a trial of an 
alternative PERT preparation is recommended (GPP)
Several studies have shown increased efficacy of PERT 
with the addition of a PPI, as PERT may be inhibited by 
gastric acid.108–110 However, the data are not consistent, 
with some studies showing no benefit.111 112 Specifically 
in pancreatic cancer, one study suggests a PPI may help 
reduce further pancreatic atrophy,113 but studies are 
limited by heterogenous cohorts.110 111
Given the conflicting data, and the potential for long- 
term complications of PPI use, including Clostridium 
difficile infection, hypomagnesaemia, nausea and diar-
rhoea,114 115 the addition of a PPI is a second- line treat-
ment for the management of PEI.
Optimum storage of enzymes (below 25°C) to 
prevent deterioration of function during storage is 
important.116–119 Each PERT product functions slightly 
differently at different pHs and timings,120–122 so consid-
ering the use of an alternative PERT product may be 
beneficial, particularly in cases where gastric transit is 
altered.
Statement 4.9: Patients with PEI receiving enteral feeds usually 
tolerate semielemental (peptide) preparations. However, where 
malabsorption symptoms persist, enzymes can be flushed via the 
feeding tube every 2 hours or added to the feed itself (GPP; 93% 
agreement)
Semi- elemental (peptide) feeds require less PERT to 
achieve complete lipolysis than polymeric feeds123; there-
fore, peptide feeding is recommended for patients with 
PEI who are receiving enteral feeds. When considering 
a choice of feed product, it is sensible to consider the 
total fat content and the proportion of medium- chain 
and long- chain triglycerides as well as the polysaccha-
ride content. This information, alongside nutritional 
requirements, fluid needs and tolerance, will assist in 
the selection of an appropriate feed. Effective mixing 
of feed with enzymes is difficult to achieve, especially 
with jejunal feeding, and administration of the enzymes, 
either as flushes or mixed directly with the feed, has been 
documented,124 125 but evidence is limited, with no safety 
or stability data available (box 2). Jejunal feeding will, 
theoretically, reduce stimulation of the pancreas126 and 
Box 2 Administration of PERT with enteral feeds
Powdered enzymes and feeding tubes
NB. Once mixed, use all products immediately. Do not leave to 
stand
Giving PERT as flushes: mix 1 g scoop pancreatin powder (Pancrex 
V Powder, Essential Pharmaceuticals, UK) with 50 mL sterile water. 
Shake well and immediately flush via a feeding tube. Do not give with 
other medication. Do not flush between the feed and the enzyme as 
this will reduce the mixing of the feed with the PERT. Administer every 
2 hours hours throughout enteral feeding, increase dose of PERT if 
needed.
Mixing PERT with feed: add 1–2 g Pancrex V Powder directly to the 
feed in a feeding reservoir. Shake well. Hang straight away and for 4 
hours hours only, increase dose of PERT if needed. (NB. Some feeds 
congeal when PERT is added - discuss with a tertiary centre dietitian 
prior to adding PERT to feed)
Flushing granules/mini- microspheres via large bore tubes 
(>CH20): mix with an acidic juice (such as Fortijuce (Nutricia Clinical 
Care, UK); Ensure Plus Juce (Abbott Nutrition, UK); Fresubin Jucy Drink 
(Fresenius Kabi, UK)) and flush via the feeding tube every 2 hours 
hours throughout enteral feeding, increase dose of PERT if needed
PERT, pancreatic enzyme replacement therapy
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may mean that patients are more likely to require PERT 
compared with those receiving gastric feeding.
Statement 4.10: When malabsorption has been corrected, 
nutritional status and bowel symptoms should improve; thus, 
monitoring of these symptoms should support ongoing treatment 
or dose escalation (GPP; 95% agreement)
To assess the need for PERT dose escalation, nutritional 
and symptom assessments can be used as summarised in 
table 2.
Differential diagnosis/treatment failures
Statement 5.1: When symptoms continue, despite treatment with 
pancreatic enzymes, clinicians should ensure that PERT products 
are being taken correctly, the dose has been adequately escalated 
and other conditions have been excluded (GPP; 100% agreement)
Treatment with PERT does not completely normalise 
digestion, and undertreatment is common, with many 
patients continuing to experience symptoms of malab-
sorption, placing them at risk of nutritional deficiencies. 
A study in Germany showed significant improvement in 
GI symptoms, pain and QoL in both newly diagnosed 
patients and those with established CP, following review 
of PERT (p<0.001), demonstrating the benefit of dose 
review.10
No treatment is 100% effective, but the steps in box 3 
should help to optimise management of PEI. If symptoms 
of PEI continue, despite optimising PERT dose, then 
other causes should be considered. Small bowel bacterial 
overgrowth (SBBO) was reported in 36% of patients with 
CP in a meta- analysis of nine studies.127
Bile acid diarrhoea, sometimes referred to as bile 
acid malabsorption (BAM) should also be considered; 
however, while the prevalence of this condition in 
patients with PEI is unknown, many patients with pancre-
atic disease have undergone cholecystectomy as part of 
the management of gallstone disease,128 which is associ-
ated with a risk of BAM.129 130
Two studies have shown an increased prevalence of PEI 
in patients with IBS- D,131 132 but the prevalence of func-
tional symptoms in patients with exocrine dysfunction is 
unknown.
In summary, once dose is optimised, ongoing symp-
toms should be investigated by taking a structured 
history and performing coeliac serology, investigation for 
SBBO using a glucose hydrogen breath test, colonoscopy 
with colonic biopsies and a selenium homocholic acid 
taurine (SeHCAT) scan. Other causes of ongoing symp-
toms should be investigated as per the British Society 
Table 2 Evaluation of the need for PERT dose escalation: nutritional and symptom assessments
Anthropometric Biochemical Clinical Dietary
 ► Weight changes in relation to 
nutritional intake (unexplained 
weight loss / failure to gain 
weight)
 ► Functional changes (grip 
strength, sit- to- stand times, 6 
min walk)
 ► Micronutrient status (iron, 
ferritin, B12 and folate, fat- 
soluble vitamins, selenium, 
zinc, magnesium, copper, 
clotting)
 ► Glycaemic control (HbA1c 
and random glucose)
 ► Inflammatory markers for 
assessment of accuracy of 
micronutrients (CRP)
 ► Stool frequency, texture, 
colour, appearance, 
presence of oil, floating/
difficult to flush,
 ► Flatulence, bloating, 
abdominal pain
 ► Medication that may 
mask symptoms (opioids, 
ondansetron, iron 
supplements, etc)
 ► 24- hour dietary 
recall with relevant 
PERT dose to assess 
adherence and ratio of 
PERT with nutrition
 ► Food avoidance due to 
abdominal symptoms
 ► Avoidance of fat- 
containing products
 ► Nutritional adequacy 
of diet
CRP, C reactive protein; HbA1c, haemoglobin A1c; PERT, pancreatic enzyme replacement therapy.
Box 3 Practical guidance for the management of 
continued symptoms despite commencement of PERT
Timing and dosing
 ► Ensure that the correct dose of enzymes is prescribed; minimum 
of 50 000 units lipase per meal and 25 000 units lipase per snack. 
Many patients require more than this for adequate digestion. 
Escalate the dose and monitor for effect
 ► Check PERT is taken appropriately, that is, with all food and milky 
drinks, spread throughout the meal rather than taking at the start 
or end of the meal
 ► Ensure PERT is being taken with all intake, for example, nutritional 
supplements, milky drinks, eating outside the home, snacks
Preventing denaturing of the enzyme
 ► Check how the PERT is stored (<25°C: avoid storage in direct sun-
light, cars, near heat sources such as kettles)
 ► Consider gastric acid suppression
Factors affecting interpretation of symptoms
 ► Exclude constipation and overflow diarrhoea
 ► Check if any other medication that may be causing abdominal 
symptoms is being taken, for example, laxatives, chemotherapy, 
metformin, antiemetics
If symptoms are not controlled
 ► If symptoms remain despite a dose of ≥10 000 units lipase/kg/day, 
then other causes of the symptoms should be considered before 
increasing the dose of PERT further
 ► Other causes of loose stools should be investigated, for example, 
SBBO, IBD, BAM, infection, coeliac disease, lactase deficiency, oth-
er food intolerances (see online supplemental table S2 for further 
details)
BAM, bile acid malabsorption; IBD, inflammatory bowel disease; PERT, 
pancreatic enzyme replacement therapy; SBBO, small bowel bacterial 
overgrowth
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of Gastroenterology guidelines for the investigation of 
chronic diarrhoea in adults.133
Long-term follow-up in patients with PEI
Statement 6.1: atients with PEI often have ongoing problems with 
malnutrition, malabsorption and bowel symptoms; therefore, long-
term follow-up is recommended (GPP; 100% agreement)
Long- term support is not easily accessible for patients 
with pancreatic disease in the UK, with a survey of UK 
practice demonstrating that most patients were not 
followed up after discharge,134 resulting in inconsistent 
advice, often provided by non- specialists. A lack of guid-
ance on the management of GI symptoms, diet and diges-
tion has been identified as the primary unmet need of 
both patients and their carers.12 In benign disease, GI 
symptoms may have a long- term impact on QoL in those 
with AP and CP.135 136
Long- term follow- up should address issues with educa-
tion, the management of PERT and should provide 
formal provision for long- term monitoring of nutritional 
markers and micronutrient status.137 This nutritional 
follow- up should include clinical, anthropometric and 
biochemical measures of nutritional status,137 138 and 
the development of a structured annual assessment 
(figure 1) could follow the model established for coeliac 
disease.138 Clinicians need to be pragmatic; the assess-
ment of patients with rapidly progressing disease should 
focus on QoL and management of symptoms, whereas 
long- term health must be a consideration in those with 
benign disease or those who have undergone treatment 
with curative intent (table 3).
Statement 6.2: Based on the literature search, no studies have 
been published to support a direct association between PEI and 
bone health. However, there is a high prevalence of osteoporosis 
and osteopenia in patients with pancreatic diseases that also 
result in PEI. Therefore, the best practice would be to implement 
routine monitoring of bone mineral density in pancreatic diseases 
(GPP; 100% agreement)
Limited data are available to support a conclusive link 
between PEI and bone health, and no studies were iden-
tified from the literature search that investigated a direct 
association (see details in the online supplemental mate-
rial).
Min et al139 reported that 31/45 (68.9%) patients with CP 
and PEI had either osteoporosis or osteopenia. A statistically 
significant association between low FEL-1 and low bone 
mineral density was reported in patients with PEI and CP, as 
assessed by X- ray (p<0.05), but not by dual X- ray absorptiom-
etry (DXA)—the latter being the gold standard for assessing 
bone mineral density.140 Patients on PERT had higher 
bone mineral density, as assessed by DXA (p<0.05). In 167 
patients with osteoporotic bone fractures, it was found that 
PEI (low FEL-1) was more frequent compared with non- 
fracture controls141: 34% of patients with osteoporosis had 
FEL-1 levels<200 µg/g, and FEL-1 levels were 65% lower in 
patients than in healthy controls. Furthermore, vitamin D, 
parathyroid hormone and calcium levels correlated with 
FEL-1 level (p<0.01).139
Finally, in an uncontrolled study, 13 of 14 patients with 
CP, all of whom had PEI, had either osteoporosis or osteo-
penia.142 No association was identified between osteopo-
rosis/osteopenia and the secretin test or faecal fat excretion.
A systematic review and meta- analysis of the prevalence of 
osteoporosis and osteopenia in CP identified eleven studies 
and 10 were included in the meta- analysis: seven articles and 
three conference proceedings. This meta- analysis of 513 
patients found that 23.4% of patients with CP had osteopo-
rosis, 39.8% had osteopenia and 65% had either osteopo-
rosis or osteopenia.143 Only one of the studies included in 
the systematic review by Duggan et al. (2014a) was retrieved 
in the broad literature search for the current systematic 
review,142 and none were retrieved following the applica-
tion of search filters. Of the 11 studies in the Duggan et al. 
(2014a) review, five144–148 reported an association between 
low bone mineral density and low FEL-1, while one study149 
found no such association.
The National Institute for Health and Care Excel-
lence guideline for pancreatitis137 recommends bone 
mineral density assessment, by DXA scan, every 2 years 
for those with CP.137 The HaPanEU guidelines150 recom-
mend that, as well as regular DXA scanning, all patients 
with CP should receive basic preventative measures to 
protect against the deterioration of bone mineral density, 
including adequate diet (particularly calcium and 
vitamin D intake), regular weight- bearing exercise and 
the avoidance of smoking and alcohol. For pancreatic 
diseases other than CP, given the morbidity and mortality 
associated with osteoporosis and fracture, as well as the 
preventable nature of osteoporosis, it seems prudent to 
recommend routine monitoring of bone mineral density 
using DXA scans in benign or curative disease.
Adverse events
Statement 7.1: PERT is not associated with any significant 
complications (grade 1A; 100% agreement)
There are many RCTs examining the efficacy of PERT, 
and all report safety data for the duration of the trial. 
Some of these are open- label extensions, up to 12 months, 
but there is a paucity of RCTs examining the long- term 
effects of PERT.
Industry- funded studies report mild abdominal pain as 
an adverse event (AE) in patients with CP (3/34) but no 
patients withdrew as a result of an AE.151 Whitcomb et al. 
identified 8/25 patients reporting AEs (flatulence, change 
in bowel habit, increased bowel frequency, hypoglycaemia 
and hyperglycaemia) in a trial exploring the use of PERT in 
a mixed cohort of patients with CP, or pancreatic resection, 
who were taking 72 000 units lipase with meals and 36 000 
units lipase with snacks.152 Interestingly, there were 8/29 AEs 
of similar nature in the placebo group.
A 6- month open- label extension in 48 patients already 
established on PERT due to CP or pancreatic surgery 
found four patients reported AEs potentially associated 
with treatment: weight gain (n=1), abdominal distension 
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(n=1), flatulence (n=1), abdominal pain (n=1) and diar-
rhoea (n=1). These were all classified as mild, and there 
were no withdrawals from the study as a result.153
In a cross- over trial using two different PERT products, 
the total number of AEs across both groups was reported as: 
headaches (4/46), diarrhoea (2/46), infection (3/46) and 
abdominal pain (2/46).99 Subsequently with an additional 
cohort 8/61 patients reporting AEs including constipation, 
abdominal discomfort and frequent bowel motion.91
A placebo- controlled study examining the use of PERT 
in 95 patients with type 1 DM found no difference in the 
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Figure 1 Summary of guidance. DXA, Dual- energy X- ray absorptiometry; PEI, pancreatic enzyme insufficiency; PERT, 
pancreatic enzyme replacement therapy; PPI, proton- pump inhibitors.
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units lipase with meals and 20 000–30 000 units lipase with 
snacks) and the control group; however, a reduction in mild 
and moderate hypoglycaemia was observed in the interven-
tion group at the end of the study.85 The most common AEs 
reported were headache, infection, pain, diarrhoea and 
dyspepsia; the incidence of each AE was not specified, but 
the overall incidence was the same in both the intervention 
and placebo groups. Changes in glycaemic control, due to 
PERT in patients with existing PEI, were only reported as 
sufficient to cause a change in management in one patient 
in a cohort of 36 patients with DM as part of a larger study 
consisting of 54 patients.154 There was no treatment- related 
AEs in the non- diabetic group.154
While these trials are small, they are all consistent in 
results. Regardless of trials not reporting serious AEs, 
fibrosing colonopathy (FC) cannot be ignored.
Statement 7.2: There is limited evidence to suggest that long-term 
use of very high-dose PERT may be associated with fibrosing 
colonopathy in children with CF, resulting in a dose restriction of 
10 000 units lipase/kg/day in this population (grade 1C; 100% 
agreement)
Comments
Cases of FC were first reported in 1992 and are thought 
to be associated with high doses of PERT (>19 000 units 
lipase/kg/day in the initial reports).155 Causal factors, 
including the presence of Eudragit L30D-55 acrylic 
resin within the enteric coating, were debated,156 but the 
initial research into this was discredited.157 Contributing 
factors were summarised as young age, previous intestinal 
surgery, meconium ileus and the use of corticosteroids, 
deoxyribonuclease and H2 blockers, and all cases were 
reported in children with CF.158–160
Patients who presented before the formation of stric-
tures were identified as having reversible symptoms that 
resolved on lowering the dose of PERT, suggesting the 
risk increased with higher doses. However, following the 
publication of case reports describing the presentation 
of FC in neonates who had not received any PERT, the 
debate over the mechanism behind the development of 
FC continues.160 161 At present, a maximum dose of 10 000 
units lipase/kg/day is recommended for children with 
CF. There is no maximum dose proposed for adults or 
children with non- CF- related PEI. Recognition features 
of FC are documented in table 4.
Use in pregnancy and breastfeeding
Statement 8.1: Further work is required to confirm the efficacy 
and safety of PERT during pregnancy and breastfeeding; although 
the authors have experience of successful use in pregnancy, the 
numbers are small and there are no published data. Malabsorption 
should be avoided in pregnancy (GPP; 93% agreement)
The systematic literature search did not identify any arti-
cles concerning the use of PERT in pregnancy or breast 
feeding. Essential fatty acids are required for brain and 
retinol development in the first 8 weeks of gestation.159 
Thus, it is important that adequate PERT is maintained 
in pregnancy.
Summary
This document serves as an evidence- based guide for 
the diagnosis and treatment of PEI. Data were derived 
Table 3 Long- term follow- up recommendations
Patients with benign disease and those who have 
undergone curative treatment for malignant disease Patients undergoing palliative management
Anthropometric and 
functional assessment
 ► Body weight
 ► Grip strength
 ► Mid- arm muscle circumference as appropriate
 ► CT scans can be assessed for muscle mass if available
 ► 6- min walk tests/sit- to- stand function tests if more detailed 
functional assessment is required
 ► DXA scans should be carried out every 2 years
 ► Body weight
 ► Grip strength/mid- arm muscle circumference 
as appropriate
Clinical  ► Assessment of bowel symptoms: stool frequency, colour
 ► Presence of abdominal bloating/wind
 ► Postprandial abdominal pain
 ► Factors impacting on QoL
 ► Change in medication (especially opioids and anti- emetic/
anti- diarrhoeal medications)
 ► Compliance with treatment
 ► Implementation of lifestyle advice (smoking, alcohol 
cessation, weight- bearing exercise, sunlight exposure)
 ► Factors impacting on QoL
 ► Assessment of bowel symptoms: stool 
frequency/colour
 ► Presence of abdominal bloating/wind
 ► Postprandial abdominal pain
 ► Change in medication (especially opioids and 
antiemetic/antidiarrhoeal medications)
 ► Compliance with treatment
Biochemical  ► Vitamin A, D, E
 ► Clotting studies (vitamin K)
 ► Parathyroid hormone
 ► Magnesium
 ► Zinc, copper, selenium
 ► Full blood count and iron studies
 ► Vitamin B12 and folate
 ► ESR/CRP
 ► Glucose and HbA1c
 ► Full blood count, iron studies, CRP
 ► Glucose and HbA1c
CRP, C reactive protein; DXA, dual X- ray absorptiometry; ESR, erythrocyte sedimentation rate; HbA1c, haemoglobin A1c; QoL, quality of life.
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through a pragmatic review of the literature, and conclu-
sions were assessed by a multidisciplinary panel of experts 
in pancreatology at the 2019 Annual Meeting of the 
Pancreatic Society of Great Britain and Ireland.
The strengths of this work are the comprehensive 
nature of the assessment and the focus on the practical 
aspects of manging PEI. Also addressed are areas of 
uncertainty, or areas where practice is difficult or vari-
able, such as diagnostic tests and treatment of patients 
whose symptoms are vague or refractory to PERT.
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